Metformin May Up Survival in Older Men With Moderate CKD Metformin May Up Survival in Older Men With Moderate CKD

Veterans with type 2 diabetes and moderate chronic kidney disease fared well on metformin in an observational study; more research is needed to see whether this is also the case in other patient populations.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Related Links:

Abstract Extracellular superoxide dismutase (SOD3), one member of the antioxidant defense system and a superoxide scavenger, has been noted to be downregulated in the kidneys of diabetic mice and is characterized by a heparin-binding domain that can anchor the protein to the endothelium and extracellular matrix. The association of the serum and urinary SOD3 levels with diabetic nephropathy in different stages has never been evaluated. It remains unclear how urinary SOD3 changes in different renal diseases. We recruited 98 Taiwanese patients with type 2 diabetes and 10 patients with early chronic kidney disease (CK...
Source: Am J Physiol Renal P... - Category: Urology & Nephrology Authors: Tags: Am J Physiol Renal Physiol Source Type: research
Conclusion: Our pilot study indicates that Grx may be a useful marker for assessing the degree of oxidative stress in CKD, however this needs further investigation in a larger prospective patient cohort.Nephron
Source: Nephron - Category: Urology & Nephrology Source Type: research
CONCLUSION: The first random abnormal urine ACR has a good PPV for the diagnosis of CKD in patients with type 2 diabetes, so multiple random urine ACR tests might not be necessary to diagnose patients with type 2 diabetes as having persistent microalbuminuria and CKD. A simpler diagnostic model for diagnosing renal disease might improve patient compliance, efficiency of testing, and implementation of health interventions. Reduced testing would also be expected to result in reduced cost from a health care expenditure perspective. PMID: 30315036 [PubMed - in process]
Source: Canadian Family Physician Medecin de Famille Canadien - Category: Primary Care Authors: Tags: Can Fam Physician Source Type: research
SIGNIFICANCE OF URINARY 11-DEHYDRO-THROMBOXANE B2 IN AGE-RELATED DISEASES: FOCUS ON ATHEROTHROMBOSIS. Ageing Res Rev. 2018 Sep 28;: Authors: Simeone P, Boccatonda A, Liani R, Santilli F Abstract Platelet activation plays a key role in atherogenesisis and atherothrombosis. Biochemical evidence of increased platelet activation in vivo can be reliably obtained through non-invasive measurement of thromboxane metabolite (TXM) excretion. Persistent biosynthesis of TXA2 has been associated with several ageing-related diseases, including acute and chronic cardio-cerebrovascular diseases and cardiovascular ris...
Source: Ageing Research Reviews - Category: Genetics & Stem Cells Authors: Tags: Ageing Res Rev Source Type: research
We examined changes in the nephron index in type 2 diabetes patients with early stage chronic kidney disease (stages 1-3), enrolling 15 patients and retrospectively analysing the follow-up data. After follow-up at 5.4 years, we observed no significant changes in the estimated glomerular filtration rate; the nephron index, however, was significantly reduced between the baseline and the follow-up. We propose that the nephron index may be potentially useful as a biomarker for monitoring the decline of renal function in the early stages of diabetic chronic kidney disease patients. PMID: 30245879 [PubMed]
Source: International Journal of Nephrology - Category: Urology & Nephrology Tags: Int J Nephrol Source Type: research
Globally 422 million adults are estimated to have type 2 diabetes (T2D), a condition that increases the risk of chronic kidney disease [1]. Chronic kidney disease refers to an estimated glomerular filtration rate (eGFR)  
Source: Primary Care Diabetes - Category: Primary Care Authors: Tags: Original research Source Type: research
Authors: Madievsky R Abstract Type 2 diabetes mellitus often goes hand in hand with cardiovascular and renal comorbidities. Stroke, myocardial infarction, heart failure, and chronic kidney disease are high-risk complications of type 2 diabetes that contribute to morbidity and mortality. Recent clinical trials have uncovered evidence that certain antidiabetic agents may confer cardiovascular and/or renal benefits such as reduced cardiovascular and all-cause mortality and reduced need for renal replacement therapy. Two landmark trials in particular, EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortal...
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
Authors: Martin WP, Docherty NG, Le Roux CW Abstract INTRODUCTION: Cardiovascular and renal disease accounts for a substantial proportion of the morbidity and mortality associated with obesity and type 2 diabetes mellitus (T2DM). Bariatric surgery is associated with improved long-term cardiovascular and renal outcomes. Areas covered: All major case-control, cohort, and randomized controlled trial studies of bariatric surgery in adults with T2DM were screened and data on prespecified cardiovascular and renal outcomes collated. Bariatric surgery reduces all-cause mortality and risk of cardiovascular disease, albuminu...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
AbstractPurpose of ReviewThe DEVOTE study compared the cardiovascular safety of two basal insulins, degludec, and glargine U100 in patients with type 2 diabetes (T2D) at high risk for cardiovascular disease (CVD). In this review, we summarize the results of DEVOTE and provide a clinical perspective.Recent FindingsDEVOTE was a phase 3b, multicenter, international, treat-to-target, double-blind, event-driven trial. Patients with T2D>  50 years of age with prior CVD or>  60 years of age with CVD risk factors were randomly assigned to receive either degludec (n = 3818) or insulin glarg...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
ConclusionIn hypertriglyceridemic patients treated with fenofibrate, the association with a combined lipid lowering nutraceutical seem to be more effective in optimizing residual hypertriglyceridemia than pravastatin 40  mg, while being more tolerable and having similar effect on LDL-C plasma level.
Source: High Blood Pressure and Cardiovascular Prevention - Category: Cardiology Source Type: research
More News: Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Metformin | Study | Urology & Nephrology